D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).
暂无分享,去创建一个
E. Braunwald | T. Nafee | C. Gibson | M. Kerneis | A. Plotnikov | M. Yee | G. Chi | F. Alkhalfan | Fahad Alkhalfan
[1] Alireza Sepehri Shamloo,et al. Diagnostic Value of D-Dimer in Acute Myocardial Infarction Among Patients With Suspected Acute Coronary Syndrome , 2018, Cardiology research.
[2] S. Goldhaber,et al. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial , 2017, Thrombosis and Haemostasis.
[3] H. Naruse,et al. Prognostic Value of Combination of Plasma D-Dimer Concentration and Estimated Glomerular Filtration Rate in Predicting Long-Term Mortality of Patients With Stable Coronary Artery Disease. , 2017, Circulation journal : official journal of the Japanese Circulation Society.
[4] M. Gul,et al. Predictive values of D-dimer assay, GRACE scores and TIMI scores for adverse outcome in patients with non-ST-segment elevation myocardial infarction , 2017, Therapeutics and clinical risk management.
[5] G. Palareti,et al. Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[6] Murali Krishna Gurram,et al. Effectiveness of D-Dimer as a Screening Test for Venous Thromboembolism: An Update , 2014, North American journal of medical sciences.
[7] G. Lip,et al. d-Dimer elevation and adverse outcomes , 2014, Journal of Thrombosis and Thrombolysis.
[8] S. Goldhaber,et al. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. , 2014, American heart journal.
[9] F. Breuckmann,et al. Impact of d-Dimers on the Differential Diagnosis of Acute Chest Pain: Current Aspects Besides the Widely Known , 2014, Clinical Medicine Insights. Cardiology.
[10] I. Pabinger,et al. Biomarkers for prediction of venous thromboembolism in cancer. , 2013, Blood.
[11] A. T. ten Cate‐Hoek,et al. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease , 2013, Thrombosis and Haemostasis.
[12] G. Stone,et al. D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy , 2013, Journal of Thrombosis and Thrombolysis.
[13] O. Chassany,et al. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. , 2012, Thrombosis research.
[14] A. Gori,et al. Thrombosis and acute coronary syndrome. , 2012, Thrombosis research.
[15] Paul Burton,et al. Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[16] A. Shimony,et al. Meta-analysis of usefulness of d-dimer to diagnose acute aortic dissection. , 2011, The American journal of cardiology.
[17] S. Hayes,et al. Fibrin D-Dimer Concentration, Deep Vein Thrombosis Symptom Duration, and Venous Thrombus Volume , 2011, Angiology.
[18] Xiaoying Li,et al. Measurement of D-dimer as aid in risk evaluation of VTE in elderly patients hospitalized for acute illness: a prospective, multicenter study in China. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.
[19] L. Wallentin,et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome , 2010, Thrombosis and Haemostasis.
[20] Georg Heinze,et al. Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.
[21] J. Mega,et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.
[22] F. Klok,et al. Elevated d‐dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta‐analysis , 2009, Journal of thrombosis and haemostasis : JTH.
[23] P. Moerloose,et al. D‐Dimer for venous thromboembolism diagnosis: 20 years later , 2008, Journal of thrombosis and haemostasis : JTH.
[24] Filippo Crea,et al. La inflamación en los síndromes coronarios agudos: mecanismos e implicaciones clínicas , 2004 .
[25] A. Turpie,et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. , 2004, Archives of pathology & laboratory medicine.
[26] F. Bernardi,et al. Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia , 2003, Circulation.
[27] Jeffrey S. Ginsberg,et al. Decrease in sensitivity of D-dimer for acute venous thromboembolism after starting anticoagulant therapy , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[28] A. Siegbahn,et al. Coagulation activity and clinical outcome in unstable coronary artery disease. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[29] G. Lowe,et al. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. , 1995, The American journal of cardiology.
[30] V. Fuster,et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.
[31] V. Fuster,et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.